Oral Thin Films Global Market Report 2024

An oral thin film (OTF) is an extremely thin polymeric film designed for application in the mouth. The primary purpose of oral thin films is to deliver therapeutic substances into the oral cavity or the gastrointestinal tract, facilitating absorption and direct transportation into the circulatory system.

The main types of oral thin films include sublingual films and fast-dissolving dental/buccal films. Sublingual films rapidly dissolve under the tongue, facilitating quick absorption through the tissue and direct entry into the bloodstream. These films are often used in the treatment of conditions such as opioid misuse disorder recovery. Additionally, oral thin films are employed in the treatment of various conditions like schizophrenia, migraine, opioid dependence, nausea, and vomiting. These films are typically distributed through hospital pharmacies, retail pharmacies, and other relevant distribution channels.

The oral thin films market research report is one of a series of new reports that provides oral thin films market statistics, including oral thin films industry global market size, regional shares, competitors with an oral thin films market share, detailed oral thin films market segments, market trends and opportunities, and any further data you may need to thrive in the oral thin films industry. This oral thin films market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral thin films market size has grown rapidly in recent years. It will grow from $4.07 billion in 2023 to $4.6 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The growth observed in the historical period can be attributed to factors such as improved patient compliance due to the ease of administration provided by oral thin films, the suitability of these films for use in pediatric and geriatric patients, the ability to achieve rapid drug delivery, the management of chronic diseases through this delivery method, and the popularity of over-the-counter (OTC) medications available in this format.

The oral thin films market size is expected to see rapid growth in the next few years. It will grow to $7.65 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The anticipated growth in the forecast period can be attributed to factors such as increased use of oral thin films in specialty pharmaceuticals, the expanding scope of precision medicine, the rising demand for oral thin films in mental health medications, the development of oral vaccines, and the incorporation of oral thin films in telemedicine services. Key trends expected in the forecast period include advancements in drug delivery technologies, the integration of remote care services, efforts to enhance bioavailability, the convenience of travel and on-the-go usage, and the formulation of allergen-free oral thin films.

The growth of the oral thin film market is being fueled by the increasing demand for thin film drug delivery systems. These films offer a convenient and fast-dissolving method for delivering medications, serving as a versatile drug delivery platform. Notably, oral thin films (OTF) are self-administrable, dissolve rapidly without the need for water, and are considered patient-friendly. The rising demand for thin-film drug delivery systems is evident in the global thin-film pharmaceutical products market, projected to grow from $7 billion in 2015 to over $15 billion by the end of 2024, indicating a 117% increase over a decade.

The oral thin films market is expected to witness further growth due to the increasing prevalence of schizophrenia. As a chronic mental disorder affecting thinking, emotions, and behavior, schizophrenia requires effective medication delivery. Oral thin films address challenges in treatment adherence by masking the taste, ensuring precise dosage control, and providing a rapid onset of action. According to the World Health Organization, approximately 24 million people worldwide, or 0.32% of the population, suffer from schizophrenia. This prevalence contributes to the growing demand for oral thin films in addressing the therapeutic needs of individuals with schizophrenia.

Key players in the oral thin films market are strategically focusing on innovative products to drive market revenues. Rizaport, an oral thin-film formulation containing rizatriptan benzoate, is one such product launched by IntelGenx Technologies Corp. in September 2021. Rizaport, an effective triptan, is administered through an oral soluble film, offering a therapeutic alternative for migraine patients. This mode of administration is particularly advantageous for those with dysphagia and migraine-related nausea.

Product approvals are playing a crucial role in market dynamics, as demonstrated by IntelGenx Technologies Corp.'s FDA approval for Rizafilm in April 2023. Rizafilm, an orally soluble film administering Rizaport outside the US, provides migraine patients with a quick-dissolving and effective alternative without the need for swallowing a tablet. This approval further solidifies the position of oral thin films in addressing various patient needs.

In September 2022, LTS LOHMANN Therapie-Systeme AG, a Germany-based company specializing in drug delivery systems, acquired Tapemark Inc. Tapemark Inc., a US-based Contract Development and Manufacturing Organization (CDMO), is renowned for its expertise in transdermal drug delivery systems and oral thin films, enhancing LTS's capabilities in these areas.

Major companies operating in the oral thin films market include ZIM Laboratories Limited, NAL Pharma, Cure Pharmaceutical Holding Corp., IntelGenx Corp., Kyu Kyu Pharmaceutical Co. Ltd., Sunovion Pharmaceuticals Inc., Seoul Pharma Co. Ltd., Aquestive Therapeutics Inc., Shilpa Therapeutics Pvt. Ltd., Mylan Inc., LIVKON Pharmaceuticals Pvt. Ltd., Panacea Biotec Ltd., Adare Pharmaceuticals Inc., APR Applied Pharma Research SA, BioDelivery Sciences International Inc., Sumitomo Dainippon Pharma Co. Ltd., Indivior PLC, LTS Lohmann Therapie-Systeme AG, Tesa Labtec GmbH, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., Novartis International AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline PLC, Bayer AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Novo Nordisk A/S, AstraZeneca plc

North America was the largest region in the oral thin film market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral thin film market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oral thin film market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The oral thin films market consists of sales of orally disintegrating and orally dissolving films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.